Japanese Journal of Lung Cancer最新文献

{"title":"Usefulness of the High-sensitivity Lung Cancer Compact Panel™ with Cytological Specimens","authors":"D. Minami, N. Takigawa, A. Tada, Yasuhiro Nakajima, N. Miyahara, Yasuyuki Mizumori, M. Ueda, Yoshiharu Sato, K. Morikawa, A. Kanehiro","doi":"10.2482/haigan.62.989","DOIUrl":"https://doi.org/10.2482/haigan.62.989","url":null,"abstract":"━━ Objective. We verified the usefulness of a new next-generation sequencing modality with the Lung Cancer Compact Panel (cid:11853) using cytological specimens. Study Design. From December 2021 to February 2022, the wash fluid of lung tumors from 10 patients obtained using endobronchial ultrasonography (EBUS) with a guide sheath (GS), EBUS transbronchial needle aspiration (EBUS-TBNA), and pleural effusion puncture was examined with the Lung Cancer Compact Panel (cid:11853) . We examined the patientsʼ medical records to obtain information on the analysis success rate and detection rate of gene mutations in consecutive cases searched for driver gene mutations. Results. Ten patients (6 lung adenocarcinoma, and 1 each of lung squamous cell carcinoma, small-cell lung cancer, renal cell carcinoma, and organizing pneumonia) and 12 samples (7 from brushing, 2 from EBUS-TBNA, 1 from a transbronchial biopsy [TBB] plus brushing, 1 from a TBB, and 1 from brushing) were examined using the Lung Cancer Compact Panel (cid:11853) . We successfully analyzed all tests in all 10 patients (100%). EGFR L858R, KRAS G12D, or KRAS G12V was detected in lung adenocarcinoma patients. KRAS G12V was detected in the lung squamous cell carcinoma patient. The amounts of nucleic acids from the pleural effusion puncture and EBUS-TBNA were sufficient for the analyses. Conclusion. The Lung Cancer Compact Panel (cid:11853) was useful for detecting gene mutations using cytological specimens.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44016633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Sarcomatoid Carcinoma Using Nivolumab Plus Ipilimumab Combination Immunotherapy: a Case Report","authors":"Hiroki Watanabe, Yuihci Murai, Asumi Suzuki, Ikumi Yamagishi, E. Ogata, T. Miyabayashi, Akira Youkou, Masatoshi Watanabe, T. Abe","doi":"10.2482/haigan.62.996","DOIUrl":"https://doi.org/10.2482/haigan.62.996","url":null,"abstract":". ABSTRACT ━━ Background. Pulmonary pleomorphic carcinoma, a subtype of sarcomatoid carcinoma, is a rare lung malignancy. This cancer is usually resistant to chemo- and radiotherapy, and no standard treatment proto-cols are currently available. We herein report a case of sarcomatoid carcinoma in a patient who responded to combination therapy using nivolumab plus ipilimumab. Case. A 62-year-old man who was a current smoker was re-ferred to our hospital with right lower extremity paresis. Computed tomography revealed a mass in the right upper lung, and magnetic resonance imaging showed multiple brain metastases. Endobronchial ultrasound-guided transbronchial needle aspiration of the mass revealed sarcomatoid carcinoma with a low expression of programmed cell death ligand-1 (PD-L1), and the tumor proportion score was 10%, being classified as clinical stage IVB (cT3N0M1c [BRA]). Following stereotactic radiotherapy to the brain lesions, he was administered combination immunotherapy using nivolumab (360 mg/kg every 3 weeks) and ipilimumab (1 mg/kg every 6 weeks). We observed shrinkage of both lung and brain lesions, which was considered a partial response, and he showed only mild immunotherapy-induced toxicity. Conclusion. Immune checkpoint inhibitors may serve as an effective therapeutic option in patients with sarcomatoid carcinoma; combination therapy using these agents may provide an improved therapeutic benefit in such cases. (","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43668811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity and Prognostic Impact of Sarcopenia in Patients with Advanced Non-small-cell Lung Cancer","authors":"S. Ito, H. Hayashi, Y. Matsumoto, Risa Nakano, Yuta Yasukochi, T. Haraguchi, H. Inoue","doi":"10.2482/haigan.62.975","DOIUrl":"https://doi.org/10.2482/haigan.62.975","url":null,"abstract":"━━ Objective. This study clarified the details concerning sarcopenia as a comorbidity and the relationship between sarcopenia and the prognosis in patients with advanced non-small-cell lung cancer. Study Design. We retrospectively studied 39 patients with stage IV advanced non-small-cell lung cancer and an Eastern Cooperative Oncology Group Performance Status of 0-1. After classifying patients into the non-sarcopenia or sarcopenia group based on their grip strength, gait speed, and psoas muscle index, the proportion in the sarcopenia group was determined. The overall survival (OS) was then compared between patients with and without sarcopenia and by the severity of sarcopenia. Results. Sarcopenia was a comorbidity in 41%, and the sarcopenia group had a sig-nificantly worse OS than the non-sarcopenia group (median, 11.0 vs. 17.9 months, p<0.05). Furthermore, the OS de-creased with increasing severity of sarcopenia (log-rank test for trend, p<0.05). Conclusion. In advanced non-small-cell lung cancer, the rate of sarcopenia comorbidity is high, even in patients with a good Performance Status, and an accurate evaluation of sarcopenia is necessary to predict the prognosis","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46880912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role and Issues of Physicians in Industrial Accident Compensation Insurance System for Mesothelioma Development","authors":"Taiki Fukujin, Sayuri Kageyama, Kanako Komaru, Yoshiaki Nakajima, Taeko Fujihara, S. Yamanaka, Koro Suzuki, Keiichi Matsushima, Takao Migita","doi":"10.2482/haigan.62.983","DOIUrl":"https://doi.org/10.2482/haigan.62.983","url":null,"abstract":". ABSTRACT ━━ Objective. Mesothelioma patients can apply to the Industrial Accident Compensation Insurance System. However, the evaluation of occupational exposure is a heavy load for physicians. The current status of asbestos exposure interviews has not been clarified. Study Design. A questionnaire survey was conducted on patients, and a stepwise regression analysis was conducted with application (certification) for Industrial Accident Compensation Insurance System as the dependent variable and three “physicianʼs response” items and five “rea-sons for application for Industrial Accident Compensation Insurance System” items as independent variables. Re-sults. Patients were more likely to apply for workersʼ compensation insurance when they received more information from their physicians (b=0.276, t[88]=2.336, p =0.021, β =0.242). We also found an increase in applications for Industrial Accident Compensation Insurance System when there was an increase in advice and suggestions from patient groups (b=0.569, t[88]=5.373, p ＜ 0.05, β =0.497). Conclusion. It is important to inform patients about applying to the Industrial Accident Compensation Insurance System, and it is necessary to establish a consultation support system at medical institutions and to deepen cooperation with patient groups","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43509565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"61st Tohoku Chapter Meeting","authors":"","doi":"10.2482/haigan.62.1061","DOIUrl":"https://doi.org/10.2482/haigan.62.1061","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43425854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Advanced Anaplastic Lymphoma Kinase-positive Lung Adenocarcinoma During the Third Trimester of Pregnancy","authors":"Yuta Kodama, Takashi Kohnoh, Masao Hiroshima, Y. Tsushima, Nozomi Goto, Atsushi Nakase, Mari Tanaka, Masayasu Inagaki, Ryota Ito, T. Yokoyama","doi":"10.2482/haigan.62.1009","DOIUrl":"https://doi.org/10.2482/haigan.62.1009","url":null,"abstract":"━━ Background. Lung cancer is a rare complication of pregnancy. Lung cancer may be diagnosed at an advanced stage because respiratory symptoms can be mistakenly perceived as pregnancy-related, and radio-logical examinations will probably be avoided due to concerns regarding fetal exposure. Case. A pregnant woman in her late thirties complained of cough that started from approximately the 26 th week of gestation, gradually re-sulting in dyspnea and appetite loss. Because a chest X-ray performed during the 37 th week of gestation revealed opacity in the entire left lung field, she was immediately admitted to our hospital. Computed tomography revealed total atelectasis of the left lung accompanied by pleural effusion, bilateral hilar and mediastinal lymphadenopathies, and multiple nodular shadows in the right lung. Considering the possibility of carcinomatous pleuritis due to lung cancer, continuous suction drainage of the left pleural effusion was immediately initiated. The follow-ing day, her infant was delivered via cesarean section. Pathological and genetic examinations of the pleural effusion sample demonstrated adenocarcinoma and rearrangement of the anaplastic lymphoma kinase (ALK) gene. After initiating alectinib treatment on the 5 th day of hospitalization, the tumor promptly decreased in size and the therapeutic effect has been maintained for more than 1 year. No malignant tumors or developmental anomalies have been observed in her infant. Conclusion. Lung cancer in women of reproductive age is characterized by a relatively high frequency of harboring certain driver gene mutations, which can progress rapidly. Thus, chest X-ray imaging should be performed for patients with persistent respiratory symptoms. Additionally, considering the possibility of the transmission of maternal cancer to offspring, pathological examinations of the motherʼs pla-centa and postnatal follow-up of the infant are important. ( JJLC. 2022;62:1009-1013)","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47080568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Anaplastic Lymphoma Kinase-rearranged Squamous Cell Lung Cancer Treated with Sequential ALK-tyrosine Kinase Inhibitor Therapy: a Case Report","authors":"R. Ozawa, H. Kuraishi, Yuki Takeuchi, Shunnosuke Tanaka, M. Yamamoto, I. Hase, T. Masubuchi, Hidetoshi Satomi, I. Ito, Shigeru Koyama","doi":"10.2482/haigan.62.1001","DOIUrl":"https://doi.org/10.2482/haigan.62.1001","url":null,"abstract":"━━ Background. Anaplastic lymphoma kinase (ALK) rearrangement is a rare subset of squamous cell lung cancer (SCC). The efficacy of ALK-tyrosine kinase inhibitors (TKIs) in ALK-rearranged SCC patients re-mains unclear. Case. A 49-year-old Japanese woman presented to our hospital with symptoms of cough and supraclavicular fossa lymph node swelling. She was diagnosed with SCC (cT4N3M1c, cStage IVB) by a percutane-ous core needle biopsy from the supraclavicular fossa lymph node. As the patient was a non-smoking woman, and the progression of the disease was rapid, we suspected the presence of an oncogenic driver. Immunostaining and fluorescence in situ hybridization revealed the presence of an ALK fusion gene. Cytotoxic chemotherapy was not feasible because the patient was suffering from idiopathic thrombocytopenic purpura. She was therefore treated with sequential ALK-TKI therapy involving alectinib, brigatinib, and lorlatinib. The tumors decreased in size with these treatments, but the duration of the effect was shorter than expected, and she ultiamtly died 12 months after the diagnosis. Conclusion. ALK-TKIs are treatment options for ALK-rearranged SCC patients; however, their efficacy is limited. Molecular testing for the ALK fusion gene is recommended even in SCC if the patient has a background that suggests the presence of an oncogenic driver.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44150077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Limbic Encephalitis Presenting as Paraneoplastic Neurological Syndrome with Possible Involvement of Immune Checkpoint Inhibitors","authors":"Tatsuhiro Furuyama, Masahide Ueda, A. Okada, Sae Hato, Yuma Watabe, Y. Inui, Takahiro Ibaraki, Fumitaka Mito, H. Takenaka, S. Choh","doi":"10.2482/haigan.62.1048","DOIUrl":"https://doi.org/10.2482/haigan.62.1048","url":null,"abstract":"━━ Background. There have been few reports of limbic encephalitis in patients with cancer. We herein report a case of limbic encephalitis that developed after treatment with immune checkpoint inhibitors for lung cancer and improved after steroid and anticancer drug therapy. Case. A 72-year-old man visited our hospital complaining of hoarseness. Chest computed tomography (CT) showed a left hilar mass, and a transbronchial lung biopsy of the mass revealed an undifferentiated carcinoma. He was diagnosed with stage IVB non-small-cell lung cancer and treated with anticancer drugs, including pembrolizumab, from November of year X­3 to August of year X­1. Since the therapeutic effect was evaluated as a partial response, he was followed closely without treatment thereafter. At the end of January of year X, amnesic symptoms appeared, and head magnetic resonance imaging showed a high signal in both temporal lobes, leading to a diagnosis of limbic encephalitis. This encephalitis was considered a complication of treatment, being either paraneoplastic neurological syndrome (PNS) or an immune-related adverse events, so steroids were administered. Consequently, his symptoms were alleviated. On chest CT, new mediastinal lymph node enlargement (#4R) was observed, so endobronchial ultrasound-guided transbronchial needle aspiration was performed. The biopsy specimen revealed the histology of the tumor to be so undifferentiated. However, its resemblance to the histology of the primary tumor led to a diagnosis of metasta-sis. Chemotherapy was started as second-line treatment and resulted in further improvement of the neurological symptoms. Conclusion. Symptoms of PNS often precede the diagnosis of cancer, and the response to steroid treatment is considered poor. Since the delayed onset of neurological symptoms and the presence of a response to steroids in this case were not typical of PNS, we suspect that pembrolizumab influenced the development of limbic encephalitis.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48281260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Non-small Cell Lung Cancer Patient Who Was Successfully Resuscitated After Cardiac Arrest Caused by Infusion-related Reaction with Carboplatin, Paclitaxel, Nivolumab, and Ipilimumab Therapy","authors":"M. Sekikawa, Toshiyuki Sumi, Yoshimatsu Ehama, Ryota Kawamura, K. Takeda, Yuta Nagahisa, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, H. Chiba","doi":"10.2482/haigan.62.1021","DOIUrl":"https://doi.org/10.2482/haigan.62.1021","url":null,"abstract":"━━ Background. Two cycles of chemotherapy and nivolumab, an anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody, have been used as the standard therapy for advanced or recurrent non-small cell lung cancer. Clinical trials have demonstrated a significantly higher overall survival with this combination than with chemotherapy alone. However, the management of adverse events is important, as with any other regimen. Case. A 61-year-old man complaining of dyspnea was diagnosed with right upper lobe non-small cell lung cancer (cT4N2M0 cStage IIIB, PD-L1 TPS 15%). Combination therapy of carboplatin, paclitaxel, nivolumab, and ipilimumab was started, and by day 10 of treatment, the tumor had clearly shrunk on chest radiographs. During day 22 of the administration of nivolumab, the patient experienced generalized erythema and nasal obstruction, which was determined to be an infusion-related reaction (IRR) grade 2. Hydrocortisone and H1 and H2 blockers were ad-ministered, and the patientʼs symptoms rapidly improved. Immediately after restarting nivolumab, the patient experienced wheezing, hypotension, and loss of consciousness, leading to cardiopulmonary arrest. The patient did not respond to repeated intravenous adrenaline administration; therefore, he was intubated and placed on an extracorporeal membrane artificial lung (V-A ECMO), which resulted in the resumption of his pulse. Subsequently, the patient was treated with steroids and discharged without any significant complications. Conclusions. Al-though the frequency of grade ≥ 3 IRR is quite low with this combination treatment, clinicians should be aware that it remains a distinct possibility.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43917199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease","authors":"Yuta Nagahisa, Toshiyuki Sumi, M. Sekikawa, K. Takeda, Keigo Matsuura, Hiroki Watanabe, Yuichi Yamada, Yoshiko Keira, H. Chiba","doi":"10.2482/haigan.62.1038","DOIUrl":"https://doi.org/10.2482/haigan.62.1038","url":null,"abstract":"━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46631833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}